Select Publications
Journal articles
2008, 'Changes in CCR5+ cells and antigen-specific CD4+ T-cells during monotherapy with a CCR5 antagonist SCH532706 compared with combination therapy', Journal of the International AIDS Society, 11, http://dx.doi.org/10.1186/1758-2652-11-s1-p297
,2008, 'Evolution of CD4+ T-cell count in HIV-1 infected adults receiving antiretroviral therapy with sustained long-term virological suppression', Journal of the International AIDS Society, 11, http://dx.doi.org/10.1186/1758-2652-11-s1-p70
,2008, 'Episodic antiretroviral therapy increases HIV transmission risk compared with continuous therapy: Results of a randomized controlled trial', JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 49, pp. 142 - 150, http://dx.doi.org/10.1097/QAI.0b013e318183a9ad
,2008, 'Pneumonia in HIV-infected persons - Increased risk with cigarette smoking and treatment interruption', AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 178, pp. 630 - 636, http://dx.doi.org/10.1164/rccm.200804-617OC
,2008, 'HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis', The Lancet, 372, pp. 1894 - 1905, http://dx.doi.org/10.1016/S0140-6736(08)61592-5
,2008, 'Determination of clinically relevant cutoffs for HIV-1 phenotypic resistance estimates through a combined analysis of clinical trial and cohort data', JAIDS: Journal of Acquired Immune Deficiency Syndromes, 48, pp. 26 - 34
,2008, 'Determination of the underlying cause of death in three multicenter international HIV clinical trials', HIV Clinical Trials, 9, pp. 177 - 185, http://dx.doi.org/10.1310/hct0903-177
,2008, 'Disease progression and fatal outcomes in HIV-infected patients during interruption of antiretroviral treatment', Journal of Infectious Diseases, 197, pp. 775 - 775, http://dx.doi.org/10.1086/527399
,2008, 'Early changes in adipokine levels and baseline limb fat may predict HIV lipoatrophy over 2 years following initiation of antiretroviral therapy', HIV Medicine, 9, pp. 101 - 110, http://dx.doi.org/10.1111/j.1468-1293.2007.00527.x
,2008, 'Effect of Rosiglitazone on Peroxisome Proliferator-Activated Receptor gamma Gene Expression in Human Adipose Tissue Is Limited by Antiretroviral Drug-Induced Mitochondrial Dysfunction', Journal of Infectious Diseases, 198, pp. 1794 - 1803
,2008, 'Inferior clinical outcome of the CD4(+) cell count guided antiretroviral treatment interruption strategy in the SMART study: Role of CD4(+) cell counts and HIV RNA levels during follow-up', Journal of Infectious Diseases, 197, pp. 1145 - 1155, http://dx.doi.org/10.1086/529523
,2008, 'Inflammatory and Coagulation Biomarkers and Mortality in Patients with HIV Infection', PLOS Medicine, 5, pp. 1496 - 1508
,2008, 'Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial', Antiviral Therapy, 13, pp. 177 - 187
,2008, 'Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study', Journal of Infectious Diseases, 197, pp. 1133 - 1144, http://dx.doi.org/10.1086/586713
,2008, 'Nadir CD4 count and monthly income predict cervical squamous cell abnormalities in HIV-positive women in a resource-limited setting', International Journal of STD and AIDS, 19, pp. 529 - 532
,2008, 'Opportunistic Disease and Mortality in Patients Coinfected with Hepatitis B or C Virus in the Strategic Management of Antiretroviral Therapy (SMART) Study', Clinical Infectious Diseases, 47, pp. 1468 - 1475
,2008, 'Restorative interventions for HIV facial lipoatrophy', AIDS Reviews, 10, pp. 116 - 124
,2008, 'Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy - a randomized trial', Annals of Internal Medicine, 149, pp. 289 - W62
,2008, 'Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients.', AIDS, 22, pp. F17 - F24
,2008, 'Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen', AIDS, 22, pp. 2279 - 2289
,2007, 'Risk of cancers during interrupted antiretroviral therapy in the SMART study', AIDS, 21, pp. 1957 - 1963, http://dx.doi.org/10.1097/QAD.0b013e3282ed6338
,2007, 'Visceral and subcutaneous adiposity measurements in adults: Influence of measurement site', Obesity, 15, pp. 1441 - 1447, http://dx.doi.org/10.1038/oby.2007.172
,2007, 'Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count ≥ 300 cells/μL who were assigned to 7.5 MIU interleukin-2', HIV Medicine, 8, pp. 112 - 123, http://dx.doi.org/10.1111/j.1468-1293.2007.00440.x
,2007, 'Erratum: Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: Associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and hypoadiponectinemia (Diabetes Care (2007) 30, (113-119))', Diabetes Care, 30, pp. 455, http://dx.doi.org/10.2337/dc07-er02
,2007, 'Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and hypoadiponectinemia (vol 30, pg 113, 2007)', DIABETES CARE, 30, pp. 455 - 455, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000244024100062&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2007, 'A randomized, multicenter, open-label study of poly-l-lactic acid for HIV-1 facial lipoatrophy', JAIDS: Journal of Acquired Immune Deficiency Syndromes, 46, pp. 581 - 589
,2007, 'Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase', AIDS, 21, pp. 2315 - 2321
,2007, 'Effect of nucleoside reverse transcriptase inhibitors (NRTIs) on CD4 recovery for individuals on long-term, fully suppressive antiretroviral therapy (ART)', Antiviral Therapy, 12, pp. L61 - L62
,2007, 'Health-related quality of life outcomes in HIV-Infected patients starting different combination regimens in a randomized multinational trial: The INITIO-QoL substudy', AIDS Research and Human Retroviruses, 23, pp. 1215 - 1222
,2007, 'Influence of IFN gamma co-expression on the safety and antiviral efficacy of recombinant fowlpox virus HIV therapeutic vaccines following interruption of antiretroviral therapy', Human Vaccines, 3, pp. 260 - 267
,2007, 'Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV-infected adults', AIDS, 21, pp. 2445 - 2453
,2007, 'Prevalence of Metabolic Syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria', Diabetes Care, 30, pp. 113 - 119, http://dx.doi.org/10.2337/dc06-1075
,2007, 'Project phidisa: development of clinical research capacity within the South African National Defence Force', Current opinion in HIV & AIDS, 2, pp. 69 - 76
,2007, 'Substantial improvements in performance indicators achieved in a peripheral blood mononuclear cell cryopreservation quality assurance program using single donor samples', Clinical and Vaccine Immunology, 14, pp. 52 - 59
,2007, 'The development of artificial neural networks to predict virological response to combination HIV therapy', Antiviral Therapy, 12, pp. 15 - 24
,2007, 'The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulation', Clinical Infectious Diseases, 44, pp. 1475 - 1483
,2006, 'Post-trial access to tested interventions: The views of IRB/REC chair, investigators, and research participants in a multinational HIV/AIDS study', AIDS RESEARCH AND HUMAN RETROVIRUSES, 22, pp. 837 - 841, http://dx.doi.org/10.1089/aid.2006.22.837
,2006, 'A comparison of genital HIV-1 shedding and sexual risk behavior among Kenyan women based on eligibility for initiation of HAART according to WHO guidelines', JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 41, pp. 611 - 615, http://dx.doi.org/10.1097/01.qai.0000191284.62707.b7
,2006, 'A randomised trial comparing genotypic and virtual phenotypic interpretation of HIV drug resistance: The CREST study.', PLoS Clinical Trials, 1, pp. e18
,2006, 'A randomised trial of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-infected patients: The UK-Vanguard study.', PLoS Clinical Trials, 1, pp. e3 - e3, http://dx.doi.org/10.1371/journal.pctr.0010003
,2006, 'A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1', AIDS, 20, pp. 294 - 297
,2006, 'Antivirals in the management of an influenza pandemic', Medical Journal of Australia, 185, pp. S58 - S61
,2006, 'CD4+ count-guided interruption of antiretroviral treatment.', New England Journal of Medicine, 355, pp. 2283 - 2296
,2006, 'Dietary intake in HIV-infected men with lipodystrophy: relationships with body composition and metabolic parameters', Antiviral Therapy, 11, pp. L23 - L24
,2006, 'Dose-response relationship of DNA and recombinant fowlpox virus prime-boost HIV vaccines.', Human Vaccines, 2, pp. 134 - 136
,2006, 'Enfuvirtide in HIV-1-infected individuals changing therapy to a nucleoside reverse transcriptase inhibitor sparing regimen: The ALLIANCE Study', Antiviral Therapy, 11, pp. 409 - 419
,2006, 'Epilogue: Preparing for an influenza pandernic in Australia', Medical Journal of Australia, 185, pp. S80 - S80
,2006, 'Evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial (ESPRIT): Geographical and gender differences in the baseline characteristics of participants', HIV Clinical Trials, 7, pp. 70 - 85
,2006, 'Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy', HIV Medicine, 7, pp. 105 - 111
,2006, 'Nonnucleoside reverse transcriptase inhibitor fold change or plasma concentration as a predictor of virological response over 48 weeks in highly treatment experienced HIV-positive individuals', AIDS Research and Human Retroviruses, 22, pp. 338 - 341
,